Cabergoline as an adjunct for early left ventricular recovery in peripartum cardiomyopathy

Mahmod, Masliza; Chan, Cheuk; Ali, Aamir; Raza, Sanara; Wan-Ibrahim, N R; Manolis, Georgios; Rahman, Riaz; Gulati, Ankur

doi:10.5837/bjc.2011.008

Cited by 4 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On the other hand there are new evidence in favor of use of indirect prolactin inhibitors, like cabergoline and bromocriptine, to enhance more rapidly cardiac pump recovery in PPCM. This latter pleiotropic effect would also synergize in order to improve the cardiac inotropism and the cardiac output too with the pharmacodynamic effect, which these dopamine agonists dircetly exerts on the myocardium [22,23]. Indeed, although the pathophysiology of PPCM remains unclear and the avaible theories only partially explain the mechanisms under this cardiovascular disease, recent researches focus on the role of increased prolactin levels in pregnancy and during lactation period.…”

Section: Discussionmentioning

confidence: 99%

Unusual and severe peripartum cardiomyopathy: A case report

LAMANNA¹,

Vinciguerra²,

Crupano³

et al. 2021

J Cardiol Cardiovasc Med

View full text Add to dashboard Cite

Peripartum cardiomyopathy (PPCM) is a relatively rare cardiac disease that manifests in the final stage of pregnancy and in the first months after delivery in women with no preexisting heart disease. Many etiological processes have been suggested: viral myocarditis, abnormal immune response to pregnancy, excessive prolactin excretion, prolonged tocolysis and a familiar predisposition to PPCM. Its diagnosis is often delayed because its symptoms, which include fatigue, dyspnea and palpitations are nonspecific. For this reason the diagnosis of PPCM is still made by exclusion of other etiologies. The long-term prognosis, once the acute phase is over, is a function of myocardial damage, this varies from complete functional recovery to chronic HF. The outcome of PPCM is highly variable with an alevated risk of fetomaternal morbidity and mortality. We report a serious case of a 40 years old female with biamniotic bicorionic twin pregnancy (PMA) who delivered by caesarean section and developed acute PPCM on post-operative. Symptoms occurred two hours after an intramuscular injection of two vials of methylergonovine the same day of cesarean delivery. These manifested in sudden tachypnoe, tachycardia and the appearance itchy maculopapular rash on her chest. On further evaluation, ECHO revealed cardiomegaly with reduced ejection fraction (< 15%). The case was successfully managed by a multidisciplinary team, using drugs like levosimendan and cabergoline, which rapresent emerging strategy in this clinical context.

show abstract

Section: Discussionmentioning

confidence: 99%

Unusual and severe peripartum cardiomyopathy: A case report

LAMANNA¹,

Vinciguerra²,

Crupano³

et al. 2021

J Cardiol Cardiovasc Med

View full text Add to dashboard Cite

show abstract

“…Además, tiene un mayor impacto positivo en vías metabólicas con reducción de los niveles de triglicéridos, ácidos grasos libres, IGF-1, Proteína C reactiva, homocisteína, fibrinógeno y ácido úrico, e incrementa el HDL y la Vit-D 30 . Así, existen algunos reportes de caso con buenos resultados, pero bajo grado de evidencia [30][31][32] . Dado que nuestro país tiene un quiebre de stock de bromocriptina, a pesar de la escasa evidencia y la ausencia de estudios randomizados, para nuestra población se podría sugerir el uso de cabergo-lina, dado su mayor eficacia terapéutica, perfil más seguro y farmacocinética favorable, como una opción de tratamiento alternativo en la MCPP.…”

Section: Manejounclassified

Miocardiopatía periparto: revisión de la literatura

Martínez

González

2022

Rev Chil Cardiol

View full text Add to dashboard Cite

show abstract

“…В иссле-довании J.S. de Jong et al зарегистрировано значи-тельное улучшение функции ЛЖ при использовании каберголина [19], хотя имеются лишь единичные ра-боты, оценивающие его эффективность при ПКМП [19,44]. Поэтому, преждевременно рассматривать этот препарат в качестве надежной терапии карди-омиопатии вследствие малого количества клиниче-ских исследований и высокого риска серьезных ос-ложнений [46,57].…”

Section: патогенетическая терапия перипартальной кардиомиопатииunclassified